The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIconic Labs Regulatory News (ICON)

  • This share is currently suspended. It was suspended at a price of 5.375

Share Price Information for Iconic Labs (ICON)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.375
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 5.375
ICON Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notice of AGM

4 Aug 2023 16:19

RNS Number : 4036I
Iconic Labs PLC
04 August 2023
 

V2 YJ [04.08.23]

04 August 2023

 

Iconic Labs PLC

 

("Iconic" or the "Company")

 

Notice of AGM and Proposed Share Consolidation

 

Iconic Labs PLC (LSE: ICON) announces that its Annual General Meeting ('AGM') will be held on Friday, 25 August 2023 at 3.00 p.m. at the offices of RWK Goodman, 69 Carter Lane, London, EC4V 5EQ.

 

The Notice of AGM has been posted to Shareholders and will be available to view shortly on the Company's website at: https://www.iconiclabs.co.uk/documents/.

 Introduction

 

The Board proposes to consolidate the Company's share capital with the aim of improving the marketability of the ordinary shares.

 

The purpose of this document is to provide you with details of the Share Consolidation to be proposed to Shareholders at the forthcoming Annual General Meeting.

 

Background to and reasons for the Share Consolidation

As at the date of this document, the Company has 46,306,916,660 Existing Ordinary Shares in issue. The primary objective of the consolidation is to reduce the number of ordinary shares, with the intention of creating a higher share price per ordinary share in the capital of the Company, which the Board believes will make the Company and the ordinary shares more attractive to a broader range of investors.

It is therefore proposed that the 46,306,916,660 Existing Ordinary Shares of £0.00001 each are consolidated on a 10,000 for 1 basis, such that every 10,000 Existing Ordinary Shares are consolidated into 1 ordinary share of £0.1 in nominal value. It is intended that additional New Ordinary Shares will be allotted, following the AGM so that the total number of Existing Ordinary Shares is exactly divisible by 10,000 for the share consolidation. Assuming a share capital of 46,306,916,660 Existing Ordinary Shares immediately prior to the Record Date, following completion of the Share Consolidation, the Company will have 4,630,692 New Ordinary Shares in issue.

Application will be made in accordance with the Main Market Rules for the New Ordinary Shares arising from the Share Consolidation to be admitted to trading on the Main Market, subject to Shareholders passing Resolution 9 at the Annual General Meeting. It is expected that if such Resolution is passed, Admission in respect of such New Ordinary Shares will become effective and that dealings in those New Ordinary Shares will commence on 28 August 2023.

No Shareholder will be entitled to a fraction of a New Ordinary Share. Instead, their entitlement will be rounded down to the nearest whole number of New Ordinary Shares. Remaining fractional entitlements to New Ordinary Shares will be aggregated and sold on behalf, and for the benefit of, the Company. If a Shareholder holds fewer than 10,000 Existing Ordinary Shares at the Record Date, then the rounding down process will result in that Shareholder being entitled to zero New Ordinary Shares and as a result of the Share Consolidation they will cease to hold any Ordinary Shares.

 

 

EXPECTED TIMETABLE OF PRINCIPAL EVENTS

2023

Posting of the AGM Notice

2 August

Latest time and date for receipt of forms of proxy for the Annual General Meeting

 

3.00 p.m. on 23 August

 

Annual General Meeting

3.00 p.m. on 25 August

Announcement of the result of the Annual General Meeting

25 August

Record Date in respect of the Share Consolidation and final date for trading in Existing Ordinary Shares

6.00 p.m. on 25 August

Admission expected to become effective and dealings expected to commence in the New Ordinary Shares on the Main Market

8.00 a.m. on 29 August

CREST accounts expected to be credited in respect of New Ordinary Shares in uncertificated form

29 August

Expected date by which certificates in respect of New Ordinary Shares are to be despatched to certificated Shareholders

By the week commencing 11 September

 

 

- Ends -

 

For more information, please contact:

Iconic Labs

 

Brad Taylor, Chief Executive Officer

Tel: +44 (0) 7462 156238

Novum Securities Limited

David Coffman / Daniel Harris

Tel: +44 (0) 20 7399 9400

 

Yellow Jersey PR

Sarah Hollins

Annabelle Wills

Bessie Elliot

 

Tel: +44 (0) 20 3004 9512

iconic@yellowjerseypr.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOAUPURARUPWGWC
Date   Source Headline
1st May 20187:02 amRNSAnnual Accounts and Fundraising Update
26th Mar 20187:00 amRNSLandmark deal to launch CellPlan insurance in Asia
19th Mar 20187:00 amRNSGranted Innovate UK KTP for Stem Cell Research
27th Feb 20187:00 amRNSLicence Award from the Human Tissue Authority
19th Feb 20187:00 amRNSBoard Changes and Launch of Wideacademy Platform
21st Dec 20177:00 amRNSCorporate Update
2nd Nov 20177:00 amRNSRevenue generation with White Apex agreement
12th Oct 20177:00 amRNSCellPlan expansion, e-commerce platform launch UK
11th Oct 20177:00 amRNSPartner Secured to Expand into MENA & Asia-Pacific
29th Sep 20177:00 amRNSInterim Results
25th Sep 20177:00 amRNSWideacademy Update, Presenting at Investor Event
15th Aug 20177:00 amRNSRaises £750,000 to support Company's divisions
31st Jul 20177:00 amRNSResearch Licence Granted from HTA
24th Jul 20177:00 amRNSNew product to target the dental market
21st Jul 20177:00 amRNSCellPlan launches E-Commerce Platform in the UK
12th Jul 20177:00 amRNSCorporate Charity Commitment
4th Jul 20177:00 amRNSAgreement to Roll Out CellPlan in Brazil
3rd Jul 20177:00 amRNSInvestor Evening and CFO Now Employed Full-time
27th Jun 20177:00 amRNSRevenue with launch of CellPlan
22nd Jun 20173:30 pmRNSResults of AGM
22nd Jun 20177:00 amRNSAGM Statement and Notice of Investor Evening
12th Jun 20177:00 amRNSWideAcademy Strategic Update
6th Jun 20177:00 amRNSLaunch of CellPlan set to generate maiden revenues
2nd Jun 20177:00 amRNSWideCells Named 21st in Global DISRUPT 100 List
23rd May 20177:00 amRNSAttendance at British Dental Conference
15th May 20177:00 amRNSAttendance at Brazilian Conference
4th May 20172:15 pmRNSHolding(s) in Company
2nd May 20177:40 amRNSPosting of Report and Accounts and Notice of AGM
12th Apr 20171:00 pmRNSPlacing
30th Mar 20177:00 amRNSPreliminary Results
16th Feb 20177:00 amRNSBoard Appointment
31st Jan 20177:00 amRNSDirector Purchases and Grant of Options
30th Jan 20174:40 pmRNSSecond Price Monitoring Extn
30th Jan 20174:35 pmRNSPrice Monitoring Extension
26th Jan 201710:30 amRNSGrant of Options
24th Jan 20177:00 amRNSExtends CellPlan Roll Out & New Product Launch
9th Jan 20177:00 amRNSDefinitive Agreement with BioVault for CellPlan
30th Nov 20167:00 amRNSNew Revenue Stream: Stem Cell Research, Manchester
7th Nov 20167:00 amRNSLOI with 1st Cord Blood Bank to Roll Out CellPlan
24th Oct 20167:00 amRNSCorporate Update
10th Oct 20167:00 amRNSUpdate on CellPlan
27th Sep 20167:00 amRNSPartners with University of Westminster
5th Sep 20167:00 amRNSLaunches WideCells Brasil
12th Aug 20167:00 amRNSHoldings In Company
5th Aug 20167:00 amRNSUpdate on Manchester Facility and Appointments
27th Jul 20168:00 amRNSPlacing & First Day of Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.